Full speed ahead! – Hamlet Pharma adapts the clinical trial program for stand-alone use
Hamlet Pharma develops new drug candidates to treat cancer without causing significant side effects. The drug candidate Alpha1H shows specificity for tumor tissue, where it accumulates and triggers cancer cell death. The anti-tumor effects of Alpha1H have been documented in a placebo-controlled clinical trial of bladder cancer and the effects on the tumor increased with a higher dose of the drug, as demonstrated in a dose-escalation study. There were no drug-related side effects in the treated patients; a very unusual result of cancer therapy.Hamlet Pharma is now taking one more step